# US 2015/0105435 A1 · Compounds and methods for regulating integrins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105435 A1
- Document ID: US20150105435A1
- Status: Published application
- Kind: A1
- Application number: 14/517,667
- Filed: 2014-10-17
- Published: 2015-04-16
- Earliest claimed: 2012-04-20
- Assignees: Adhaere Pharmaceuticals, Inc.
- Applicants: Adhaere Pharmaceuticals, Inc.
- Inventors: Vineet Gupta
- Web page: https://patentgrep.com/patent/US20150105435A1

## CPC

- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A method for treating breast cancer, the method comprising:
administering to a patient a β2 integrin agonist having the formula
or a pharmaceutically acceptable salt thereof, wherein:
A is absent or is selected from alkyl and alkenyl,
B is absent or is selected from alkyl, alkenyl, O, S, and NR4,
X is selected from O and S,
R1 is selected from alkoxycarbonyl, aryl, heteroaryl, carbocyclyl, and heterocyclyl,
R3 is phenyl which is unsubstituted or substituted with one or two substituents independently selected from halogen, nitro, cyano, hydroxyl, thiol, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, alkyl, and carboxy, and
R4 is selected from hydrogen and alkyl; and
reducing tumor growth.

### Claim 37 (depends on 36)

The method of claim 36, further comprising administering radiation or an anti-cancer compound to the patient.

### Claim 38 (depends on 37)

The method of claim 37, comprising administering the anti-cancer compound which is paclitaxel.

### Claim 39 (depends on 36)

The method of claim 36, wherein the breast cancer is metastatic breast cancer.

### Claim 40 (depends on 36)

The method of claim 36, wherein reducing tumor growth includes reducing the number of inflammatory leukocytes recruited to the tumor.

### Claim 41 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 43 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 47 (depends on 36)

The method of claim 36, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 48

A method for treating diabetic nephropathy, the method comprising:
administering to a patient a β2 integrin agonist having the formula
or a pharmaceutically acceptable salt thereof, wherein:
A is absent or is selected from alkyl and alkenyl,
B is absent or is selected from alkyl, alkenyl, O, S, and NR4,
X is selected from O and S,
R1 is selected from alkoxycarbonyl, aryl, heteroaryl, carbocyclyl, and heterocyclyl,
R3 is phenyl which is unsubstituted or substituted with one or two substituents independently selected from halogen, nitro, cyano, hydroxyl, thiol, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, alkyl, and carboxy, and
R4 is selected from hydrogen and alkyl; and
improving the health of the patient's kidneys.

### Claim 49 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the β2 integrin agonist is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 51 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.

### Claim 55 (depends on 48)

The method of claim 48, wherein the β2 integrin agonist is:
or a pharmaceutically acceptable salt thereof.
